Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8684760 | Experimental Neurology | 2018 | 9 Pages |
Abstract
However, RAS activation alone is not sufficient for MPNST formation, and additional tumor suppressors and signaling pathways have been implicated in tumorigenesis of MPNST. Taking advantage of the rapid development of novel therapeutics targeting key molecular pathways across all cancer types, the best-in-class modulators of these pathways can be assessed in pre-clinical models and translated into clinical trials for patients with MPNST. Here, we describe the genetic changes and molecular pathways that drive MPNST formation and highlight the promise of signal transduction to identify therapies that may treat these tumors more effectively.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
AeRang Kim, Christine A. Pratilas,